New Drug Application Acceptance for Fruquintinib
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) and Innovent Biologics, Inc. (HKEX: 01801) have jointly announced the acceptance of their New Drug Application (NDA) for the combination of fruquintinib and sintilimab in treating advanced renal cell carcinoma. This significant milestone represents a hopeful advancement for patients suffering from locally advanced or metastatic renal cell carcinoma, particularly those whose treatment with prior tyrosine kinase inhibitors (TKIs) has failed.
Study Background and Results
The NDA is backed by pivotal data obtained from the FRUSICA-2 study. This was a randomized, open-label registration study focused on evaluating the efficacy and safety of fruquintinib combined with sintilimab against the use of axitinib or everolimus alone for second-line treatment. Remarkably, the study met its primary endpoint of progression-free survival (PFS), showcasing significant improvements in secondary endpoints such as overall response rate (ORR) and duration of response (DoR). These results highlighted a tolerable safety profile with no new safety concerns emerging from the combination therapy.
Clinical Conference and Future Plans
Data from this study is expected to be disclosed at forthcoming scientific conferences, emphasizing HUTCHMED’s dedication to addressing unmet medical needs in kidney cancer therapy. According to Dr. Michael Shi, Head of R&D and Chief Medical Officer at HUTCHMED, this NDA submission marks an essential step in making this combination therapy available to patients, alongside ongoing research to unveil further potential for the treatment across various cancer types.
Strategic Response from Innovent
In a response marking the NDA acceptance, Dr. Hui Zhou, Senior Vice President of Innovent, remarked that this development is significant for patients facing advanced renal cell carcinoma in China. With sintilimab, branded as TYVYT®, now having its tenth indication endorsed through this NDA, both companies aim to enhance treatment accessibility and efficacy.
Previous Approvals and Conditional Usage
Prior to this announcement, the combination of fruquintinib and sintilimab received conditional approval from the China National Medical Products Administration (NMPA) for treating advanced mismatch repair proficient (pMMR) endometrial cancer patients who have failed previous systemic therapies. Such approvals indicate a growing recognition of the potential and therapeutic impact of these drug combinations.
Insights into Kidney Cancer
The landscape of kidney cancer remains challenging, with a staggering reported 435,000 new diagnoses globally in recent years. Particularly in China, approximately 74,000 new cases were identified, with renal cell carcinoma comprising around 90% of these instances. As kidney cancer treatment options continue to evolve, the partnership between HUTCHMED and Innovent serves as a beacon of hope, emphasizing innovation in combating such formidable challenges.
The Role of Fruquintinib
Fruquintinib plays an essential role as a selective oral inhibitor targeting three vascular endothelial growth factor receptors (VEGFR) - 1, 2, and 3. This drug aims to inhibit tumor angiogenesis, promoting a safer therapeutic avenue with better focus on the target without compromising the patient’s overall wellbeing. Developed in conjunction with Eli Lilly, fruquintinib has shown efficacy in treating patients with metastatic colorectal cancer after prior therapies.
Innovative Approaches to Immunotherapy
Sintilimab, alongside fruquintinib, highlights the collaborative efforts in enhancing immunotherapy effectiveness. Marketed under the name TYVYT® in China, sintilimab functions as a PD-1 immunoglobulin G4 monoclonal antibody that rejuvenates the body’s immune response against cancer cells. The ongoing studies to expand its applications not only underscore its established efficacy but also promise future innovations that seek to prolong patient survival rates across various malignancies.
Conclusion
The collaboration between HUTCHMED and Innovent on fruquintinib and sintilimab exemplifies the dedication of both companies toward improving treatment outcomes for patients with advanced renal cell carcinoma. As clinical data emerges and further studies are undertaken, the industry watches eagerly to witness the impact of these efforts on public health and cancer treatment protocols worldwide.
Frequently Asked Questions
What is the significance of the NDA acceptance?
The NDA acceptance for the fruquintinib and sintilimab combination is crucial as it signifies a step forward in developing effective treatments for advanced renal cell carcinoma, addressing the unmet medical needs of patients.
What were the results of the FRUSICA-2 study?
The FRUSICA-2 study achieved its primary endpoint of progression-free survival, showing promising secondary outcomes such as improved objective response rate and duration of response.
How does fruquintinib work as a treatment?
Fruquintinib functions as an oral inhibitor of VEGFR receptors, effectively limiting tumor angiogenesis which can help in slowing cancer progression.
What are the future steps for HUTCHMED and Innovent?
Both companies plan to present detailed clinical data at scientific conferences and continue their joint efforts to explore the combination therapy’s full potential in treating various cancer types.
How does sintilimab enhance cancer treatment?
Sintilimab enhances cancer treatment by reactivating T-cell responses against cancer cells, marking it as a pivotal component in the field of immuno-oncology.
